We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

In play

17 January 2011 By Nicholas Paisner

The UK conglomerate’s shares have jumped after it said it rebuffed a seemingly punchy $3.9 bln bid for its medical unit from buyout firm Apax. Smiths has good reason to think it can get a better price. Explaining why it shouldn’t be dismantled looks harder.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)